Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 67-73 , February 2000

The challenge of p53 as prognostic and predictive factor in gliomas

  • C. Nieder

      Affiliations

    • Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
    • ,
  • S. Petersen

      Affiliations

    • Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
    • ,
  • C. Petersen

      Affiliations

    • Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
    • ,
  • H.D. Thames

      Affiliations

    • Department of Biomathematics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA

References 

    REFERENCES
  1. Fine HA. The basis of current treatment recommendations for malignant glioma. J Neurooncol. 1994;20:111–120
  2. Levin VA, Silver P, Hannigan J. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321–324
  3. Gundersen S, Lote K, Watne K. A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. Eur J Cancer. 1998;34:1565–1569
  4. Fueyo J, Gomez-Manzano C, Yung WKA, Kyritsis AP. The functional role of tumor suppressor genes in gliomas. Neurology. 1998;51:1250–1255
  5. Iwadate Y, Fujimoto S, Tagawa M. Association of p53 gene mutation with decreased chemosensitivity in human malignant glioma. Int J Cancer. 1996;69:236–240
  6. Shu HK, Kim MM, Chen P. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21 (BAX). Proc Natl Acad Sci USA. 1998;95:14453–14458
  7. Haas-Kogan DA, Kogan SS, Yount G. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys. 1999;43:399–403
  8. Baxendine-Jones J, Campbell I, Ellison D. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol. 1997;16:332–336
  9. Tada M, Matsumoto R, Iggo RD. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 1998;58:1793–1797
  10. Milner J. Structures and functions of the tumor suppressor p53. Pathol Biol. 1997;45:797–803
  11. Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg. 1998;85:1460–1467
  12. Amundson SA, Myers TG, Fornace AJ. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 1998;17:3287–3299
  13. Badie B, Goh CS, Klaver J. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther. 1999;6:155–162
  14. Kirsch DG, Kastan MB. Tumor suppressor p53: implications for tumor development and prognosis. J Clin Oncol. 1998;16:3158–3168
  15. Curran WJ, Scott CB, Horton J. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–710
  16. J Neurooncol. 1990;9:47–55
  17. Simpson JR, Horton J, Scott CB. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive RTOG clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239–244
  18. Hilton DA, Love S, Barber R, Ellison D, Sandeman DR. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery. 1998;42:724–729
  19. Kraus JA, Bolln C, Wolf HK. TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer. 1994;10:143–149
  20. Newcomb EW, Cohen H, Lee SR. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, mdm2 or bcl-2 genes. Brain Pathol. 1998;8:655–667
  21. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropath Appl Neurobiol. 1998;24:381–388
  22. Kyritsis AP, Bondy ML, Hess KR. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995;1:1617–1622
  23. Vital A, Loiseau H, Kantor G. p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathol Res Pract. 1998;194:831–836
  24. Iuzzolino P, Ghimenton C, Nicolato A. p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br J Cancer. 1994;69:586–591
  25. Shinoda J, Sakai N, Nakatani K, Funakoshi T. Prognostic factors in supratentorial WHO grade Ii astrocytoma in adults. Br J Neurosurg. 1998;12:318–324
  26. AI-Sarraj A, Bridges LR. p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg. 1995;9:143–149
  27. Bhattacharjee MB, Bruner JM. p53 protein in pediatric malignant astrocytomas: a study of 21 patients. J Neuro Oncol. 1997;32:225–233
  28. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery. 1994;35:831–838
  29. Cunningham JM, Kimmel DW, Scheithauer BW, O’Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg. 1997;86:121–130
  30. Drach LM, Kammermeier M, Neirich U. Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescence. Clin Neuropathol. 1996;15:67–73
  31. Ehrmann J, Kolar Z, Vojtesek B, Kala M, Komenda S, Oulton A. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma. 1997;44:299–304
  32. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psy. 1995;59:413–419
  33. Hwang SL, Hong YR, Chai CY, Lin HJ, Howng SL. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erb b-2 immunostaining. Kaohsiung J Med Sci. 1998;14:607–615
  34. Montine TJ, Bruner JM, Vandersteenhoven JJ, Dodge RK, Burger PC. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol. 1994;3:240–245
  35. Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC. Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol. 1997;94:369–375
  36. Rainov NG, Dobberstein KU, Bahn H. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro Oncol. 1997;35:13–28
  37. James CD, Galanis E, Frederick L. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol. 1999;15:547–553
  38. Korkolopoulou P, Christodoulou P, Kouzelis K. MDM 2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997;75:1269–1278
  39. Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol. 1998;95:617–624
  40. Pollack IF, Hamilton RL, Finkelstein SD. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 1997;57:304–309
  41. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery. 1995;37:246–254
  42. Schiffer D, Dutto A, Cavalla P. Prognostic factors in oligodendroglioma. Can J Neurol Sci. 1997;24:313–319
  43. Perry A, Jenkins RB, O’Fallon JR. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. Cancer. 1999;86:672–683
  44. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why?. J Clin Oncol. 1997;15:3423–3426

PII: S0305-7372(99)90145-7

doi: 10.1053/ctrv.1999.0145

Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 67-73 , February 2000

Article Tools